Rimeporide, a first in class Na/H exchanger-1 inhibitor, ameliorates right ventricular dysfunction and pulmonary arterial hypertension in a SuHx model

25 August 2023 (11:15 - 12:00)

Organised by:

Video

Abstract

Sign in to view the resources

Slides

About the speaker

Doctor Giuseppina Milano

University Hospital Centre Vaudois (CHUV), Lausanne (Switzerland)

7 More presentations in this session

Presentation thumbnail

  A high-throughput screening strategy identifies adenosine 5'-monophosphate as a novel enhancing molecule of the cardio-protective enzyme 5-oxoprolinase (OPLAH).

Mr J. Esquivel Gaytan (Groningen, NL)

Abstract Slides Video

Presentation thumbnail

Melanocortin 1 receptor deficiency protects against pathological cardiac hypertrophy

Ms A. Suominen (Turku, FI)

Abstract Slides Video

Presentation thumbnail

Betaine therapy of cardiac hypertrophy through inhibition of Hydroxy-carboxylic Acid Receptor 1 signaling

Miss L. Yao (Nantong, CN)

Abstract Slides Video

Presentation thumbnail

ERBB4 stimulation mitigates atrial fibrillation and remodeling in a porcine DOCA model

Doctor M. Tubeeckx (Antwerp, BE)

Abstract Slides Video

Presentation thumbnail

The anti-fibrotic effect of atrial natriuretic peptide depends on myocardial accumulation of the peptide in rat heart

Professor S. Hatem (Paris, FR)

Abstract Slides Video

Access the full session

Session thumbnail

Myocardial remodelling (1)

The Event

Event poster

ESC Congress 2023

25 August 2023 11:15 CET

You may be interested in

Congress Presentation

Pathobiological characterization of pulmonary hypertension associated with heart failure with preserved ejection fraction

Congress Session

Molecular approaches to the treatment of pulmonary hypertension

Congress Presentation

Colchicine as a therapeutic option for the treatment of pulmonary arterial hypertension (PAH) in a rat model

ESC 365 is supported by

novartis

Explore sponsored resources

ESC 365 is supported by

novartis

Explore sponsored resources